European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
M Baccarani, MW Deininger, G Rosti… - Blood, The Journal …, 2013 - ashpublications.org
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …
inhibitors, mandate regular updating of concepts and management. A European …
DNMT3A in haematological malignancies
L Yang, R Rau, MA Goodell - Nature Reviews Cancer, 2015 - nature.com
DNA methylation patterns are disrupted in various malignancies, suggesting a role in the
development of cancer, but genetic aberrations directly linking the DNA methylation …
development of cancer, but genetic aberrations directly linking the DNA methylation …
Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia
G Etienne, J Guilhot, D Rea, F Rigal-Huguet… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia
(CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years …
(CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years …
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
D Rea, FE Nicolini, M Tulliez, F Guilhot… - Blood, The Journal …, 2017 - ashpublications.org
Abstract STOP second generation (2G)–tyrosine kinase inhibitor (TKI) is a multicenter
observational study designed to evaluate 2G-TKI discontinuation in chronic myeloid …
observational study designed to evaluate 2G-TKI discontinuation in chronic myeloid …
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective …
FX Mahon, D Réa, J Guilhot, F Guilhot, F Huguet… - The lancet …, 2010 - thelancet.com
Background Imatinib treatment significantly improves survival in patients with chronic
myeloid leukaemia (CML), but little is known about whether treatment can safely be …
myeloid leukaemia (CML), but little is known about whether treatment can safely be …
The concept of treatment-free remission in chronic myeloid leukemia
S Saußele, J Richter, A Hochhaus, FX Mahon - Leukemia, 2016 - nature.com
The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic
myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is …
myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is …
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
RA Larson, A Hochhaus, TP Hughes, RE Clark… - Leukemia, 2012 - nature.com
Abstract Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients
compares nilotinib and imatinib in patients with newly diagnosed chronic myeloid leukemia …
compares nilotinib and imatinib in patients with newly diagnosed chronic myeloid leukemia …
Biomarkers for personalized oncology: recent advances and future challenges
M Kalia - Metabolism, 2015 - Elsevier
Cancer is a group of diseases characterized by the uncontrolled growth and spread of
abnormal cells and oncology is a branch of medicine that deals with tumors. The last decade …
abnormal cells and oncology is a branch of medicine that deals with tumors. The last decade …
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month …
HM Kantarjian, A Hochhaus, G Saglio… - The lancet …, 2011 - thelancet.com
Background Nilotinib has shown greater efficacy than imatinib in patients with newly
diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (CML) in chronic …
diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (CML) in chronic …